COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN

被引：0
|
作者：
Ramirz de Arellano, A. [1 ]
Hunt, B. [2 ]
Mezquita Raya, P. [3 ]
Briones, T. [1 ]
Perez, A. [1 ,4 ]
Valentine, W. J. [2 ]
机构：
[1] Novo Nordisk Pharma SA, Madrid, Spain
[2] Ossian Hlth Econ & Commun, Basel, Switzerland
[3] Hosp Torrecardenas, Clin San Pedro, Almeria, Spain
[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB69
引用
收藏
页码：A249 / A250
页数：2
相关论文
共 50 条
  • [1] Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
    Pedro Mezquita Raya
    Antonio Pérez
    Antonio Ramírez de Arellano
    Teresa Briones
    Barnaby Hunt
    William J. Valentine
    Diabetes Therapy, 2013, 4 : 417 - 430
  • [2] Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
    Mezquita Raya, Pedro
    Perez, Antonio
    Ramirez de Arellano, Antonio
    Briones, Teresa
    Hunt, Barnaby
    Valentine, William J.
    DIABETES THERAPY, 2013, 4 (02) : 417 - 430
  • [3] INCRETIN THERAPY FOR PATIENTS WITH TYPE 2 DIABETES IN SPAIN: A COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS SITAGLIPTIN
    Ramirez de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    VALUE IN HEALTH, 2013, 16 (07) : A439 - A439
  • [4] COST-EFFECTIVENESS OF LIRAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES IN THE SLOVAK REPUBLIC
    Ilavska, A.
    Uliciansky, V
    Wrona, W.
    Lacka, J.
    Czech, M.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A291
  • [5] Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
    Antonio Pérez
    Pedro Mezquita Raya
    Antonio Ramírez de Arellano
    Teresa Briones
    Barnaby Hunt
    William J. Valentine
    Diabetes Therapy, 2015, 6 : 61 - 74
  • [6] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [7] Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
    Perez, Antonio
    Mezquita Raya, Pedro
    Ramirez de Arellano, Antonio
    Briones, Teresa
    Hunt, Barnaby
    Valentine, William J.
    DIABETES THERAPY, 2015, 6 (01) : 61 - 74
  • [8] THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
    Lin, H.
    Babineaux, S.
    Lew, T.
    Lowin, J.
    Lovato, E.
    Strizek, A. A.
    Rajan, N.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [9] Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran
    Ekhlasi, Mahna
    Taheri, Saeed
    Yousefi, Nazila
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 54 - 61
  • [10] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    Diabetes Therapy, 2017, 8 : 513 - 530
12345